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Abstract
Background: Recent transcriptomic studies revived a hypothesis suggested by historical studies in rabbits that the
ratio of peripheral blood monocytes to lymphocytes (ML) is associated with risk of tuberculosis (TB) disease. Recent
data confirmed the hypothesis in cattle and in adults infected with HIV.
Methods: We tested this hypothesis in 1,336 infants (540 HIV-infected, 796 HIV-exposed, uninfected (HEU))
prospectively followed in a randomized controlled trial of isoniazid prophylaxis in Southern Africa, the IMPAACT
P1041 study. We modeled the relationship between ML ratio at enrollment (91 to 120 days after birth) and TB
disease or death in HIV-infected children and latent Mycobacterium tuberculosis (MTB) infection, TB disease or death
in HEU children within 96 weeks (with 12 week window) of randomization. Infants were followed-up prospectively
and routinely assessed for MTB exposure and outcomes. Cox proportional hazards models allowing for non-linear
associations were used; in all cases linear models were the most parsimonious.
Results: Increasing ML ratio at baseline was significantly associated with TB disease/death within two years
(adjusted hazard ratio (HR) 1.17 per unit increase in ML ratio; 95% confidence interval (CI) 1.01 to 1.34; P = 0.03).
Neither monocyte count nor lymphocyte counts alone were associated with TB disease. The association was not
statistically dissimilar between HIV infected and HEU children. Baseline ML ratio was associated with composite
endpoints of TB disease and death and/or TB infection. It was strongest when restricted to probable and definite
TB disease (HR 1.50; 95% CI 1.19 to 1.89; P =0.006). Therefore, per 0.1 unit increase in the ML ratio at three to four
months of age, the hazard of probable or definite TB disease before two years was increased by roughly 4%
(95% CI 1.7% to 6.6%).
Conclusion: Elevated ML ratio at three- to four-months old is associated with increased hazards of TB disease
before two years among children in Southern Africa. While significant, the modest effect size suggests that the ML
ratio plays a modest role in predicting TB disease-free survival; its utility may, therefore, be limited to combination
with existing tools to stratify TB risk, or to inform underlying pathophysiologic determinants of TB disease.
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Globally, Mycobacterium tuberculosis (MTB) infects about
2 billion people, causing 10 million active cases, of whom
about 500,000 cases are children [1]. It is a leading cause
of death in sub-Saharan Africa, yet practical methods to
stratify risk in this population are lacking [2,3]. Children
with MTB infection are at risk for tuberculosis (TB) di-
sease; therefore, identification of these children is im-
portant. The current tools to identify children with MTB
infection are tuberculin skin testing (TST) or interferon-
gamma release assay (IGRA). Although isoniazid (INH)
preventive therapy (IPT) is more effective in HIV-infected
individuals with a positive TST result [4], neither TST nor
IGRA are sufficiently good at predicting TB disease. In a
recent meta-analysis, a positive TST or IGRA result in
children or adults was associated with an increase in inci-
dence of about 1.4 to 2 fold with wide confidence limits
due to study heterogeneity [3]. Current World Health
Organization (WHO) guidelines do not support routine
TST or IGRA testing before IPT provision in children [5].
If individuals at risk for TB could be accurately identified,
they could be targeted for interventions to prevent TB
such as IPT. In addition, predictors of TB may offer new
insight into pathogenesis.
Recent and historical studies suggest that the peri-
pheral blood monocytes:lymphocytes ratio may be asso-
ciated with subsequent mycobacterial disease outcomes.
Fletcher et al. used whole-transcriptome microarrays to
examine leucocyte gene expression in 10-week-old BCG-
vaccinated, HIV-uninfected infants for clues as to why
some developed TB by age two years while others did
not [6]. They found that opposing levels of myeloid and
lymphoid specific gene transcripts were more frequent
among infants who later developed culture-confirmed TB
disease, than among matched controls. Since the quantity
of myeloid and lymphoid transcripts in peripheral blood is
a marker of the frequency of leucocyte subsets, the tran-
script ratio may reflect leucocyte subset frequencies. How-
ever, these were not available in their study. Nevertheless,
in support of the specific role of relative proportions of
monocytes and lymphocytes in TB pathogenesis, studies
performed between 1921 and 1930 by Florence Sabin and
colleagues demonstrated in rabbit models of TB that
‘monocyte-lymphocyte ratio in the peripheral blood might
be taken as an index of the progress and extent of the dis-
ease’ [7]. Sabin and colleagues then demonstrated that ex-
perimentally altering the ratio by depleting or increasing
monocyte frequency resulted in commensurate changes in
rabbit survival following challenge with Mycobacterium
bovis [7-9]. Recent results in cattle show in vitro that
the ratio of monocyte-derived macrophages to lympho-
cytes is associated with inhibition of mycobacterial growth
[10,11]. We recently reported that the ratio of monocytes:
lymphocytes (ML) in HIV-infected South African adults
prior to combination antiretroviral therapy initiation
(cART) was predictive of TB disease during the subse-
quent five years on cART [12]. In what appears to be the
first and only study of the role of this ratio in childhood
mycobacterial disease in 1928, Rogers studied the ML ra-
tio in 41 children with either a negative tuberculin skin
test, latent TB infection or active TB disease. He observed
that the ML ratio correlated with the extent and severity
of disease, but called for ‘the work [to] be checked up on a
larger series’ [13].
Here, we evaluated whether the peripheral blood ML
ratio at between three- and four- months of age was as-
sociated with subsequent MTB infection or TB disease
during the first two years of life in infants randomized
to either INH prophylaxis or placebo in the IMPAACT
P1041 study [14].
Methods
Study population
In IMPAACT P1041 (clinicaltrials.gov reference NCT
00080119), 544 HIV-infected and 810 HIV-exposed, un-
infected infants (HEU), 91 to 120 days of age, born to
HIV-infected mothers, were enrolled at one of three
sites in South Africa (Chris Hani Baragwanath Hospital,
Johannesburg; Tygerberg Hospital, Stellenbosch University,
Cape Town, and King Edward VIII Hospital, Durban) or at
one center in Botswana (Princess Marina Hospital,
Gaborone). Infants were randomized to receive INH 10 to
20 mg per kilogram body weight daily or placebo. Results
of the trial have been reported [14]. Informed consent for
participation in this study, specimen collection and future
research was obtained from parents/guardians under
protocols approved at each study site (University of the
Witwatersrand: #020109; Stellenbosch University: #M04/
05/026; and University of KwaZulu Natal: #T118/05)
and by the Oxford Tropical Research Ethics Committee
(Reference 508–13).
Definition of ML ratio
Investigations in P1041 included an enrollment full blood
count, including white blood cell differential count, which
was repeated three-monthly thereafter. Full blood counts
were obtained using routine flow-cytometric assays in ac-
credited laboratories.
Study endpoints
The primary outcome measure of this study was TB dis-
ease or death in HIV-infected children and latent MTB
infection, TB disease or death in HEU children within
96 weeks (with 12 week window) after randomization.
Infants were followed-up prospectively and routinely
assessed for MTB exposure and outcomes as reported
[14]. An endpoint review committee of study-team clini-
cians unaware of the study-group assignments reviewed
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endpoints. Latent MTB infection among HIV-uninfected
infants was diagnosed by TST at approximately two years
of age (and again at three and four years for a subset), or
when clinically indicated. Latent MTB infection was de-
fined as a positive TST (induration ≥5m mi nh o r i z o n t a l
diameter in HIV-infected children and ≥10 mm in HEU
children) in the absence of evidence of active disease ac-
cording to contemporary guidelines [15]. The criteria used
for categorizing TB as either possible, probable, or micro-
biologically confirmed (definite) have been previously
detailed [14].
Statistical methods
To calculate the ML ratio, the absolute monocyte count
was divided by the absolute lymphocyte count. Analysis
was performed according to a statistical analysis plan de-
veloped a priori. To model the association between ML
ratio and the primary endpoint, Cox proportional haz-
ards models were used. Scaled Schoenfeld residuals were
inspected to evaluate the proportionality assumptions of
the Cox model. Study duration was calculated as the
time from randomization to the first diagnosed episode
of TB or death, withdrawal from the study or the end of
week 108 (last visit date for patients remaining in follow-
up), whichever occurred first. Where possible we preferred
modeling continuous variables as fractional polynomials
[16,17], an approach that allows continuous variables to
be analyzed on their native scale without categorization,
and allowing for non-linear fits. We explored non-linear
fits with fractional polynomials, in all cases the best statis-
tical fit was linear.
All statistical tests were two-sided at the 5% signi-
ficance level. Poisson approximations were used to cal-
culate confidence intervals (CIs) for estimations of the
incidence rate. Bootstrapped estimates of the adjusted
hazard ratio (HR) across the ML ratio continuum were
generated with the ‘boot’ package. Statistical analyses were
performed in R (The R Foundation for Statistical Com-
puting) using the following packages ‘epiR’, ‘survival’, ‘date’
and ‘mfp’.
Results
Between December 2004 and June 2008, 1,354 infants
born to HIV-infected mothers were enrolled at a me-
dian of 96 days of age (interquartile range (IQR) 92 to
105 days). Their baseline characteristics have been re-
ported [14]. A total of 1,336 infants were eligible for this
analysis. The reasons for ineligibility were a missing full
blood count result (nine participants), implausible results
(two participants), participant not receiving INH/placebo
and not followed (three participants) or missing covariates
or outcomes (four participants). The included infants
were similar to those in the primary analysis [14]: 47.8%
(638/1,336) were male, 25.2% (136/540) of all HIV-
infected infants were receiving cARTat baseline, 7.2% (96/
1,336) had a maternal history of TB, and 9% (121/1,215)
were ever breastfed. The median WHO weight for age
z-score was −0.55 (IQR −1.45 to 0.28).
The median ML ratio at baseline was 0.13 (IQR 0.09
to 0.18). As shown in Figure 1, the distribution of ML
ratio in HIV-infected infants was significantly higher
(median 0.15 versus 0.12, P <0.001) than HEU infants.
This was consistent with the higher absolute monocyte
counts among HIV-infected infants (median 0.93 versus
0.71, P <0.001) but similar absolute lymphocyte counts
(6.02 versus 5.89, P =0.15 ) compared to HEU infants.
Baseline ML ratio is associated with TB disease free
survival
Over 1,997 infant-years, 187 infants reached the primary
endpoint of this study: TB disease (probable, possible or
definite) or death in HIV-infected infants and latent MTB
infection, TB disease or death in HEU infants. Stratified by
HIV status, the unadjusted HR per 1 unit increase in the
ML ratio was 1.20 (95% CI 1.05 to 1.38, P=0.008). Adjust-
ing for the weight-for-age z-score, receipt of cART at the
time of sampling, a maternal history of TB, breastfeeding
and receipt of INH prophylaxis, did not markedly alter the
effect estimate (HR 1.17 (1.01 to 1.34), P=0. 03 ).Incon-
trast, neither the monocyte nor lymphocyte count alone
was significantly associated with the primary study end-
point. This finding is consistent with previous studies in
adult humans [12], in rabbits [9] and in vitro (data not
shown). Adjusting for CD4% among HIV-infected infants
did not weaken the association in this group (HR 1.2;
95% CI: 1.01 to 1.43, P=0.04), nor did adjusting for ab-
solute leucocyte counts in the entire cohort (HR 1.20;
95% CI: 1.01 to 1.43).
Baseline ML ratio is associated with probable or definite
TB rather than all-cause mortality or latent MTB infection
To explore whether the ML ratio was specifically as-
sociated with TB disease or with other outcomes, we
tested whether the association between the ML ratio and
TB disease was robust to alternative endpoint definitions
(Table 1). The ML ratio was significantly associated with
elevated hazards of TB disease alone (HR 1.23, 95% CI
1.04 to 1.45, P =0.02) and with elevated hazards of TB
disease plus all-cause death (HR 1.18, 95% CI 1.02 to
1.37, P =0.02) or TB disease plus latent MTB infection
(HR1.21, 95% CI 1.04 to 1.41, P =0.02). Increasing the
stringency of the case definition by excluding individuals
with possible TB and including only definite and probable
TB diagnoses strengthened the association between ML
ratio and TB disease (HR 1.50, 1.19 to 1.89, P=0.00 6) .
The ML ratio was not significantly associated with all-
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Among HEU children, with TST at 96 weeks, 33 of 725
(4.5%) had latent MTB infection. There was no association
between baseline ML ratio and latent MTB infection
(HR 1.00, 95% CI 0.66 to 1.5, P=0.99) neither was there
evidence of interaction between ML ratio and INH pro-
phylaxis. No INH effect was observable in a model of INH
effect across the ML ratio spectrum.
The association between baseline ML ratio and TB disease
free survival is similar in HIV-infected and HEU children
The association between ML ratio and the primary end-
point was not statistically dissimilar between HIV-infected
and HEU infants (adjusted HR 1.2, 95% CI 1.01 to 1.42
versus adjusted HR 1.07, 95% CI 0.83 to 1.4 respectively;
Chi
2 test for heterogeneity with 1df: P=0.48, overall test
for effect P=0. 04 ).
Table 1 Sensitivity analysis: the association between baseline ML ratio and TB outcomes holds across TB
outcome grouping
Endpoint Number
(cases/at risk)
Multivariable regression
adjusted hazard ratio (95% CI)
a
P value
Primary endpoint: TB disease
b or death in HIV+infants; and TB disease
b,
death or latent MTB infection in HEU infants
187/1336 1.17 (1.01 to 1.34) 0.03
TB disease
b or death 166
c/1336 1.18 (1.02 to 1.37) 0.02
TB disease
b or latent MTB infection 152/1336 1.21 (1.04 to 1.41) 0.02
TB disease
b 126/1336 1.23 (1.04 to 1.45) 0.02
Probable and definite TB only 49/1336 1.50 (1.19 to 1.89) 0.006
Death 50/1336 1.25 (0.99 to 1.57) 0.06
Latent MTB infection
d 33/725 1.00 (0.66 to 1.5) 0.99
aEstimated from Cox Proportional Hazard regression models stratified by infant HIV status, modeling ML as linear variable following fractional polynomial
exploration, adjusted for weight-for-age z-score, cART receipt at baseline, maternal history of TB, ever breastfed and randomized INH prophylaxis/placebo group.
Hazard ratios are per unit increase in the ML ratio.
bPossible, probable or definite TB.
cParticipants who had TB disease (possible, probable or definite TB) and
subsequently died were only counted once, hence this number is not the sum of the TB disease and death numerators below.
dLatent MTB infection was only
assessed in HEU infants. Text in bold highlights statistically significant findings. cART, combination antiretroviral therapy; CI, confidence interval; HEU, HIV-exposed
uninfected; INH, isoniazid; MTB, Mycobacterium tuberculosis; TB, tuberculosis.
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Figure 1 Distribution of monocyte:lymphocyte (ML) ratio at enrollment shown for HEU (n=796, dashed line) and HIV-positive infants
(n=540, solid line).
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Transcriptomic studies in infants suggested that the rela-
tive proportions of myeloid and lymphoid cells in infants
have predictive value for TB risk (HF, unpublished). Con-
cordant animal studies support this notion [9], as do re-
cent studies in adults with AIDS [18]. We found that the
ML ratio in peripheral blood at around three months of
age was associated with TB disease or MTB infection-free
survival in South African children, notwithstanding con-
ventional risk factors. Per 0.1 unit increase in ML ratio at
three months of age, the hazard of probable or definite TB
disease before two years old increased by roughly 4% (ap-
proximately 1.5
0.1). While significant, the modest effect
size suggests that the ML ratio plays a modest role in pre-
dicting TB disease-free survival; its utility may, therefore,
be limited to combination with other tools to stratify
TB risk or to study pathophysiologic determinants of
TB disease.
Several factors support the ML ratio being on the cau-
sal pathway for TB development. First, monocytes are
target cells for mycobacterial growth and lymphocytes
are the major effectors for mycobacterial clearance. Sec-
ond, there appears to be a dose or gradient effect with
higher ratios being more predictive than lower ratios
across the ML ratio gradient. Third, as we demonstrated,
altered ML ratios precede active disease; hence, reverse
causality is unlikely. Fourth, our data in children are
consistent with in vitro findings. Fifth, there is overall
coherence of this finding with experimental animal and
observational adult studies. Finally, the association be-
tween the ML ratio and subsequent TB disease has par-
tial specificity. The association is stronger for the ML
ratio rather than monocyte counts and definite/probable
TB rather than possible TB. We have also recently re-
ported that the ML ratio may be associated with child-
hood malaria incidence [19]; hence, the ML ratio may
actually have pleiotropic associations with some child-
hood infectious diseases. However, the effect size seems
modest. Further studies should endeavor to assess more
detailed subsets of monocytes and lymphocytes to iden-
tify precise cellular players in this association.
The mechanistic basis for the association is not ad-
dressed in this work. It is plausible that the ML ratio re-
flects relative frequency of myeloid or lymphoid biased
hematopoietic stem cells, and that the ratio may, therefore,
reflect ontogeny driven differences in function [20,21]. This
argument remains speculative. Alternatively, the ML ratio
may reflect the relative frequency of monocytes as target
cells and lymphocytes as effectors against TB. The likeli-
hood of the latter explanation is reduced by the lack of
association between monocyte counts and/or lymphocyte
counts alone with TB outcomes. A third possible explan-
ation is that an altered ML ratio is due to a specific mono-
cyte subset defect. Since HIV infects and alters monocyte
function in a subset specific manner [22], it is possible
that HIV exposure alters monocyte functions and ratios.
The similarity in effect between HIV-infected and HEU
infants, however, mitigates the likelihood of the associa-
tion being driven by HIV infection.
Our analysis has several limitations. Firstly, the defini-
tion of TB outcomes is challenging in infants. This ana-
lysis benefits from using data from a trial where outcomes
were stringently defined and prospectively recorded, with-
out knowledge of this hypothesis. Clearly specified defini-
tions, including those delineating certainty of endpoints,
allowed evaluation of the sensitivity of our finding to alter-
native outcome definitions, including more stringent defi-
nitions of TB disease. Secondly, this observational study
cannot conclusively demonstrate a causal relationship be-
tween the ML ratio and TB disease. Mendelian randomi-
zation approaches, leveraging genetic correlates of the
ratio, may facilitate more stringent evaluation of the
association. Thirdly, although we observed association be-
tween the ML ratio and incident TB disease in all HIV-
exposed infants regardless of HIV infection status, further
studies are required to establish whether the association
is present in infants not exposed to HIV. Use of an a
priori statistical analysis plan ameliorated the likelihood
of the significant association between the ML ratios and
T Br i s kb e i n gaf a l s ed i s c o v e r yd u et om u l t i p l eh y p o -
thesis testing.
Conclusions
Our study extends observations on the ML ratio and risk
of TB disease previously seen in HIV-infected adults to
HIV-exposed infants [18]. The modest effect size sug-
gests that the ML ratio plays a modest role in predicting
TB disease risk in infants. Therefore, for clinical utility,
the ML ratio may benefit from combination with other
tools to identify at-risk infants. The replication of this
finding across animal, infant and adult studies neverthe-
less suggests that the ML ratio is a pathophysiological pre-
dictor of tuberculosis disease and further study of this
trait may yield insight into why some infants succumb to
TB disease.
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